Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with BlackstoneGlobeNewsWire • 05/13/25
Prediction: These 2 Stocks Will Outperform the Market in the Next Five YearsThe Motley Fool • 05/12/25
AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/YZacks Investment Research • 05/06/25
Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 05/05/25
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/05/25
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 05/05/25
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health MonthGlobeNewsWire • 05/01/25
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to DeclineZacks Investment Research • 04/28/25
Kuehn Law Encourages Investors of Axsome Therapeutics, Inc. to Contact Law FirmGlobeNewsWire • 04/10/25
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual MeetingGlobeNewsWire • 04/04/25
AXSM Stock Down on Top-Line Data From Depression Study on SolriamfetolZacks Investment Research • 04/02/25
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A WeekInvestors Business Daily • 04/01/25